Financing ·
GT Biopharma, Inc. amended its Securities Purchase Agreement to increase the private placement of Series M 10%…
GTBPGT Biopharma, Inc.
GT Biopharma, Inc. amended its Securities Purchase Agreement to increase the private placement of Series M 10% Convertible Preferred Stock and accompanying warrants. A new purchaser joined the offering on September 18, 2026, raising the aggregate purchase price from $7,450,000 to $7,750,000 for 8,611.111 shares of preferred stock with a stated value of $8,611,111.11. The company also filed a Certificate of Increase in Delaware, raising the authorized number of Series M shares from 41,778 to 43,287. Investors retain Greenshoe Rights to purchase up to an additional $34,675,615 in stated value for $31,208,054. The company operates in the biotechnology industry, focusing on developing immunotherapies.